ChiralVision offers a solid foundation and a record of delivering quality services for active pharmaceutical ingredients (APIs), registered intermediates and complex chiral compounds for both branded pharmaceutical and generic markets. ChiralVision is the specialist in route development comprising enzymatic conversions and resolution and has an extensive experience in process development and scale-up of enzymatically prepared chiral compounds. We can develop new and proprietary routes to existing compounds, or take an existing synthesis and develop a scalable process, all with smart use of biocatalysis. By using commercially available (bulk) enzymes, enzyme costs per kilogram of end product can be kept to an absolute minimum. The target for enantiomeric excess is always >99%.